Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board

(NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has joined the Scientific Advisory Board for a potential cure for Hepatitis B Virus (HBV), that causes liver disease in approximately 350 million people globally and 1 million deaths every year.

Professor Lok is a leading clinical researcher. She is the Alice Lohrman Andrews Research Professor in Hepatology in the Department of Internal Medicine, at Michigan Medicine in Ann Arbor, Michigan and is the Director of Clinical Hepatology and Assistant Dean for Clinical Research in the University of Michigan Medical School.

Dr. Lok's research focuses on the natural history and treatment of hepatitis B and C, and the prevention of liver cancer. She has published more than 550 papers on viral hepatitis and liver diseases, and has co-authored five editions of the American Association for the Study of Liver Diseases (AASLD) Guidelines on Hepatitis B. She is a former President of the AASLD. Dr. Lok was one of the top 1% of most cited scientists in the world for the decade 2002-2012.

“I was intrigued by Enochian’s Inventor and Co-Founder, Dr. Serhat Gumrukçu’s presentation at an important scientific meeting in December 2019, where he cited the early data and very innovative strategy to potentially cure HBV. Since then, the Company has made significant progress and I am very pleased to now become more engaged and contribute to advancing the science towards clinical trials,” Dr. Lok said. Dr. Carol Brosgart, the Chair of the Scientific Advisory Board and member of the Enochian Board of Directors, said, “I am very excited that Anna is joining Dr. Fabien Zoulim and Dr. Peter Revill as members of the Scientific Advisory Board. Anna brings decades-long expertise in clinical research. They are all among the top researchers in the field of Hepatitis, creating a remarkably high-powered group.”

“Enochian is entering a key phase to accelerate the development of a potential cure for HBV with promising results thus far,” said Dr. Mark Dybul, Enochian’s CEO. “As announced previously, the FDA accepted our Pre-Investigational New Drug (IND) application. As we prepare to advance through the regulatory process, it is timely for someone with Anna’s extensive clinical research expertise to join our Scientific Advisory Board.”

About Enochian BioSciences, Inc. Enochian BioSciences, Inc. is a biopharmaceutical company focused on developing innovative platforms for gene-modified cellular and immune therapies to potentially cure and treat deadly diseases. The company’s gene-modified cell and immune therapy platforms can potentially be applied to multiple indications, including HIV/AIDS, Hepatitis B, all Corona and Influenza viruses, and Oncology. For more information, please visit Enochianbio.com Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences’ most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.